which is already struggling to establish itself in the COPD market. The drug is positioned as a follow-up product to GSK’s blockbuster Advair/Seretide, but the company is now facing generic ...

We assessed socioeconomic covariates (mean copayments, total copayments, and unique brand-to-generic prescription ... least one severe COPD exacerbation during the baseline assessment period; (4) ...

Approved yesterday by the FDA, Trelegy Ellipta is the first ever daily single-inhaler to combine a triple therapy for COPD, and could ... as the first Advair generic looks to be just around ...

According to Forbes, the most prescribed Glucagon-Like Peptide-1 GLP-1 agonist in 2023 was Semaglutide, the market leader for obesity medications and the generic form of Ozempic, Wegovy ...

Qnovia, Inc., a pharmaceutical company developing inhaled therapeutics across a variety of indication areas leveraging its proprietary inhaled drug delivery platform, the RespiRxtm, today announced ...

For patients with chronic obstructive pulmonary disease (COPD), budesonide-glycopyrrolate-formoterol does not improve ...

a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...